ClinicalTrials.gg
Not yet recruitingNCT07075237Updated Sep 29, 2025

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

A Phase 4 interventional study of Paliperidone Palmitate Injection (PP1M) in Schizophrenia, sponsored by Jiangsu Province Nanjing Brain Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Jiangsu Province Nanjing Brain Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Planned enrollment
66th of 115
120 · median 178
Started
2025
with 1 other
Phase 4
42 of 115
5 open now
Registered
111th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 66th largest by planned enrollment, is one of 2 that started in 2025, is one of 42 in phase 4, and was the 111th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function

Read the detailed description

This study plans to enroll 120 patients diagnosed with schizophrenia per DSM-5 criteria who have achieved clinical stability on oral antipsychotic therapy. Patients will receive monotherapy with Paliperidone Palmitate Injection. Assessments will be conducted at baseline, Day 35±7, Day 91±7, and Day 175±7. Adverse events and concomitant medications will be recorded during follow-up visits.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Paliperidone Palmitate
  • Oral antipsychotics
  • Social function|
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients or inpatients meeting diagnostic criteria forschizophrenia;
  2. Aged 18-65 years (inclusive), regardless of gender;
  3. Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline;
  4. Signed by the patient and/or guardian;

Exclusion criteria

Exclusion Criteria:

  1. Comorbid psychiatric diagnoses other than schizophrenia;
  2. Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses;
  3. >450 ms (male) or >460 ms (female);
  4. History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal/violent tendencies;
  5. Current or history of tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or severe extrapyramidal symptoms (EPS);
  6. Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic regimens of different compounds);
  7. or inefficacy to risperidone or paliperidone; 8. Pregnancy, lactation, planned pregnancy, or failure to use effective during the study;

9. Other conditions deemed unsuitable by the investigator. \|

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Switching from Oral Antipsychotics to Paliperidone Palmitate Injection in the Treatment of Schizophrenia Patients

    Drug: Paliperidone Palmitate Injection (PP1M)

Interventions

  • DrugPaliperidoneStudies of PaliperidonePaliperidone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment). To avoid missed doses, administration is permitted ±7 days around the scheduled monthly date.

06

What researchers measure

Primary outcomes

  1. The Positive and Negative Syndrome Scale (PANSS)

    The Positive and Negative Syndrome Scale (PANSS) is a standardized clinical assessment tool used to evaluate the severity of symptoms in patients with schizophrenia. It measures three domains: Positive Symptoms (e.g., hallucinations, delusions), Negative Symptoms (e.g., social withdrawal, blunted affect), General Psychopathology (e.g., anxiety, guilt). Scores are derived from a 30-item structured interview, with each item rated on a 7-point scale (1=absent to 7=extreme). Higher total scores indicate more severe symptomatology. Widely used in research and clinical settings, PANSS helps monitor treatment efficacy and disease progression.

    Time frame: Day 175±7

Secondary outcomes

  1. Personal and Social Performance (PSP)

    The Personal and Social Performance (PSP) scale is a clinician-rated assessment tool designed to measure an individual's social and personal functioning across four key domains: socially useful activities (e.g., work/studies), personal/social relationships, self-care, and disruptive/aggressive behaviors. Scores range from 0 to 100, with higher values indicating better functional capacity. Widely used in mental health research and clinical practice, it provides a standardized way to evaluate functional impairment and recovery progress in conditions like schizophrenia.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  2. EuroQol-5 Dimensions (EQ-5D)

    The EQ-5D (EuroQol-5 Dimensions) is a standardized, self-reported questionnaire used to assess health-related quality of life. It evaluates five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated across three or five severity levels (depending on the version: EQ-5D-3L or EQ-5D-5L). Widely applied in health economics and clinical research, it aids in cost-effectiveness analyses and treatment outcome comparisons.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  3. Clinical Global Impression-Severity (CGI-S)

    A single-item, 7-point clinician rating (1=normal to 7=extremely severe) evaluating global psychiatric illness severity. Not diagnosis-specific, it provides rapid assessment of symptom intensity across mental disorders.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  4. Extrapyramidal Symptom Rating Scale (SAS)

    A clinician-administered tool assessing drug-induced movement disorders, including parkinsonism, dystonia, and akathisia. Rates 10 items (e.g., rigidity, tremor) on a 0-4 severity scale (total range 0-40). Widely used to monitor antipsychotic side effects.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  5. Barnes Akathisia Rating Scale (BARS)

    A structured scale measuring antipsychotic-induced akathisia (motor restlessness). Combines: Subjective distress (0-5) Objective movements (0-5) Global severity (0-5) Critical for differentiating akathisia from anxiety/agitation.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  6. Abnormal Involuntary Movement Scale (AIMS)

    A 12-item observational tool screening tardive dyskinesia severity. Focuses on facial/oral, extremity, and truncal involuntary movements (rated 0-4 per item). Requires baseline/follow-up assessments for longitudinal monitoring.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

Other outcomes

  1. electrocardiogram (ECG)

    To analysis whether ECG QT Interval of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  2. Alanine Aminotransferase (ALT)

    To analysis whether ALT level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  3. Glucose (GLU)

    To analysis whether GLU level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  4. Total Cholesterol (TC)

    To analysis whether TC level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  5. High-Density Lipoprotein Cholesterol (HDL-C)

    To analysis whether HDL-C level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  6. Low-Density Lipoprotein Cholesterol (LDL-C)

    To analysis whether LDL-C level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  7. Triglycerides (TG)

    To analysis whether TG level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

  8. Prolactin (PRL)

    To analysis whether PRL level of participants show any significant trend with time changes.

    Time frame: Baseline, Day 35±7, Day 91±7, Day 175±7

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2026, 12 months later.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 20, 2025
StartEst.
Oct 2025
Primary completionEst.
Oct 2026
CompletionEst.
Mar 2027
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075237
Lead sponsor
Jiangsu Province Nanjing Brain Hospital
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 29, 2025

Study contacts

Hao Tang, MD
Contact
tanghao997@163.com
+86 18913821366

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion